Attached files
| file | filename |
|---|---|
| 8-K - ACCLARENT ACQUISITION 8-K - JOHNSON & JOHNSON | acclarenteightk.htm |
Exhibit
99.1
Contact:
Ethicon,
Inc.
Barbara
Montresor
732-865-2488
(mobile)
J&J Corporate
Communications
Bill
Price
732-524-6623
(office)
732-668-3735
(mobile)
J&J Investor
Relations
Louise Mehrotra
Louise Mehrotra
732-524-6491
Stan
Panasewicz
732-524-2524
Ethicon
Completes Acquisition of Acclarent
Opportunity
to Create New Growth Platform in Surgical ENT Market
SOMERVILLE,
N.J., Jan 20, 2010 -- Ethicon, Inc., announced today that it has completed the
acquisition of Acclarent, Inc., following clearance under the Hart-Scott-Rodino
Antitrust Improvement Act. Acclarent is a privately held medical
technology company dedicated to designing, developing and commercializing
devices that address conditions affecting the ear, nose and throat
(ENT). Ethicon announced its agreement to acquire Acclarent on
December 16, 2009.
"By
bringing together the strengths and experiences of the two companies, we create
a unique way to innovate in the surgical ENT space," said Gary Pruden, Johnson
& Johnson Company Group Chairman with responsibility for
Ethicon. "The surgical ENT market is underpenetrated and there is
opportunity to help more patients restore their quality of life with
less-invasive surgical solutions. We look forward to working with
Acclarent and its customers to do this."
About
Ethicon
Ethicon,
Inc., a Johnson & Johnson company, is a trusted, world-wide leader in
surgical care. For over a century, Ethicon has continuously
introduced innovations in wound closure, general surgery, wound management,
women's health and urology and aesthetic medicine that fulfill the Company's
vision: Restoration of body and of life. For more information, visit
www.ethicon.com.